Excited to share our newly published article in Nature Reviews Urology @NatRevUrol, “Rare Prostate Cancer Histologies: Detection, Characteristics and Treatment,” led by Drs. Spiess and Melão. @SpiessPhilippe @UrogerliMD @katcollmd @neerajaiims @PGrivasMDPhD @AndreaNecchi This comprehensive review highlights the diagnostic, molecular, and clinical features of both common and rare prostate cancer histologic subtypes, including mucinous, intraductal, ductal, neuroendocrine, sarcomatoid, and adenoid cystic (basal cell) carcinomas. We also explore advances in pathology, imaging, molecular profiling, immunotherapy and precision oncology, while addressing important unmet clinical needs and future research directions.   Full article available: nature.com/articles/s41585-0…

Learn from Johns Hopkins GU pathology faculty 🔬 Contemporary Issues in GU Pathology Prostate • Bladder • Kidney • Testis • Adrenal 📅 Feb 5–6, 2027 · Pre-recorded lectures + live Q&A CME/MOC accredited Register: hopkinscme.cloud-cme.com/cou… #PathTwitter #gupath

After three decades of extraordinary service to Brown University Health, our beloved Molecular Laboratory Manager, Missy Andrade, is beginning an exciting new chapter.   Together with Dr. Cinthia Jackson, Missy helped build our Molecular Pathology Laboratory from the ground up and played an instrumental role in shaping it into the outstanding, first-class laboratory it is today. Her expertise, dedication, leadership, and steadfast commitment to excellence in patient care have left a lasting impact on our laboratory, our department, and the many colleagues, trainees, and patients she has served over the years.   Beyond her remarkable professional contributions, Missy has been a trusted colleague, a cherished friend, and an invaluable member of our Molecular Pathology family. We are profoundly grateful for everything she has given to Brown University Health and Molecular Lab   Missy, thank you from the bottom of our hearts for three decades of exceptional service. We wish you every happiness and success in your new position. You leave behind an extraordinary legacy, and you will be very dearly missed.

The ISUP Stockholm meeting was a tremendous success - an unforgettable gathering and an inspiring milestone for the future of precision pathology and management of GU malignancies. On September 12, 2026, 112 experts and colleagues from around the world came together at the Grand Hôtel Stockholm for a multidisciplinary expert consultation on precision biomarker testing in bladder and prostate cancer. We are living through one of the most transformative periods in the history of pathology. Cancer diagnosis is no longer defined by morphology alone. Increasingly, diagnosis, classification, prognosis, therapeutic selection, and disease monitoring are being shaped by biomarkers, molecular testing, and artificial intelligence.Our Stockholm conference embraced this transformation. Together, we examined the current and future landscape of biomarker testing in bladder and prostate cancer, including standardization of testing and reporting, specimen selection, liquid biopsy, artificial intelligence, digital pathology, and the critical unanswered questions that will shape the next generation of research and clinical practice. This meeting was not the conclusion of a process -it was the beginning of one. The conversations will continue. The evidence will evolve. Our recommendations will be refined, challenged, and strengthened. New technologies will emerge, new biomarkers will enter clinical practice, and new questions will undoubtedly arise. What will remain constant is our shared commitment to advancing science, improving standards, and ultimately providing better care for our patients. I am deeply grateful to our outstanding Working Group Chairs - Michelle Downes, Antonio Lopez-Beltran, Gladell Paner @GladellPaner , and Alessia Cimadamore, my co-Chair, Arno van Leenders - and to every member of our Working Groups for their extraordinary expertise, dedication, preparation, and countless contributions. My sincere thanks also go to every attendee who traveled to Stockholm and contributed ideas, questions, debate, and perspective. A very special thank to Katrina Collins, @katcollmd Nancy Greenland, and Alessia Cimadamore @AlessiaCim , who devoted countless hours to organizing the meeting and managing the many logistical details behind the scenes. @IntSocUropath

Wonderful to see Hui Min and Busra presenting our poster, largest series of renal synovial sarcoma at ECP meeting

Do you recognize this unusual breast cancer variant? What are its molecular features? In the upcoming September issue of Histopathology @Histo_Journal, Drs.Yihong Wang, Liu Liu and colleagues @BrownPathology reported driver mutations involving TP53, PIK3CA, BRCA2, RB1, AKT3, and multiple DNA-repair genes using comprehensive molecular profiling. Particularly interesting was the first reported NTHL1 alteration in acinic cell-like breast carcinoma, with germline mutation and tumor copy-number loss supporting biallelic inactivation. These cases also highlighted different DNA-repair pathways, involving base excision repair (BER) and homologous recombination repair (HRR).   These findings illustrate molecular overlap among acinic cell-like carcinoma, carcinoma arising in microglandular adenosis, and triple-negative breast cancer, while emphasizing substantial intertumoral genetic heterogeneity.    Congratulations to all the authors!   Article Available:
onlinelibrary.wiley.com/shar…

Tomorrow on #pathCast 🔬 (Mahmut Akgul, MD, @BrighamWomens @harvardmed) 🎯 Challenges in Defining and Studying Urothelial Carcinoma Subtypes 📅 Aug 25 ⏰ 12 PM ET 🔴 Live: Facebook + YouTube /pathcast 🌐 pathcast.net #GUPATH #Pathology